Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls

被引:72
作者
Dautzenberg, Geraud [1 ]
Lijmer, Jeroen [2 ]
Beekman, Aartjan [3 ]
机构
[1] Altrecht Inst Mental Hlth Care, Dept Old Age Psychiat, Utrecht, Netherlands
[2] OLVG Hosp, Dept Psychiat, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, GGZ InGeest, Amsterdam, Netherlands
关键词
dementia; mild cognitive impairment; MoCA; old age psychiatry; spectrum-bias; validation; NORMATIVE DATA; IMPAIRMENT; DEMENTIA; VALIDATION; DEPRESSION; CRITERIA; VERSION; METAANALYSIS; SCALE; CARE;
D O I
10.1002/gps.5227
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective/methods The Montreal Cognitive Assessment (MoCA) is an increasingly used screening tool for cognitive impairment. While it has been validated in multiple settings and languages, most studies have used a biased case-control design including healthy controls as comparisons not representing a clinical setting. The purpose of the present cross-sectional study is to test the criterion validity of the MoCA for mild cognitive impairment (MCI) and mild dementia (MD) in an old age psychiatry cohort (n = 710). The reference standard consists of a multidisciplinary, consensus-based diagnosis in accordance with international criteria. As a secondary outcome, the use of healthy community older adults as additional comparisons allowed us to underscore the effects of case-control spectrum-bias. Results The criterion validity of the MoCA for cognitive impairment (MCI + MD) in a case-control design, using healthy controls, was satisfactory (area under the curve [AUC] 0.93; specificity of 73% less than 26), but declined in the cross-sectional design using referred but not cognitive impaired as comparisons (AUC 0.77; specificity of 37% less than 26). In an old age psychiatry setting, the MoCA is valuable for confirming normal cognition (greater than or equal to 26, 95% sensitivity), excluding MD (greater than or equal to 21; negative predictive value [NPV] 98%) and excluding MCI (greater than or equal to 26;NPV 94%); but not for diagnosing MD (less than 21; positive predictive value [PPV] 31%) or MCI (less than 26; PPV 33%). Conclusions This study shows that validating the MoCA using healthy controls overestimates specificity. Taking clinical and demographic characteristics into account, the MoCA is a suitable screening tool-in an old age psychiatry setting-for distinguishing between those in need of further diagnostic investigations and those who are not but not for diagnosing cognitive impairment.
引用
收藏
页码:261 / 269
页数:9
相关论文
共 47 条
  • [1] [Anonymous], J ATTEN DISORD
  • [2] [Anonymous], WORLD ALZHEIMER REPO
  • [3] [Anonymous], 2013, Cochrane Database Syst Rev, DOI [10.1002/14651858.CD010460, DOI 10.1002/14651858.CD010460]
  • [4] Ballard DH, 2015, COMPUT NEUROSCI-MIT, P1, DOI 10.7551/mitpress/9780262028615.001.0001
  • [5] Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression - A systematic review
    Baune, Bernhard T.
    Renger, Lisa
    [J]. PSYCHIATRY RESEARCH, 2014, 219 (01) : 25 - 50
  • [6] Effects of anxiety versus depression on cognition in later life
    Bierman, EJM
    Comijs, HC
    Jonker, C
    Beekman, ATF
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 13 (08) : 686 - 693
  • [7] Meta-analysis of Cognitive Impairment in First-Episode Bipolar Disorder: Comparison With First-Episode Schizophrenia and Healthy Controls
    Bora, Emre
    Pantelis, Christos
    [J]. SCHIZOPHRENIA BULLETIN, 2015, 41 (05) : 1095 - 1104
  • [8] Improving dementia care: The role of screening and detection of cognitive impairment
    Borson, Soo
    Frank, Lori
    Bayley, Peter J.
    Boustani, Malaz
    Dean, Marge
    Lin, Pei-Jung
    McCarten, J. Riley
    Morris, John C.
    Salmon, David P.
    Schmitt, Frederick A.
    Stefanacci, Richard G.
    Mendiondo, Marta S.
    Peschin, Susan
    Hall, Eric J.
    Fillit, Howard
    Ashford, J. Wesson
    [J]. ALZHEIMERS & DEMENTIA, 2013, 9 (02) : 151 - 159
  • [9] STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies
    Bossuyt, Patrick M.
    Reitsma, Johannes B.
    Bruns, David E.
    Gatsonis, Constantine A.
    Glasziou, Paul P.
    Irwig, Les
    Lijmer, Jeroen G.
    Moher, David
    Rennie, Drummond
    de Vet, Henrica C. W.
    Kressel, Herbert Y.
    Rifai, Nader
    Golub, Robert M.
    Altman, Douglas G.
    Hooft, Lotty
    Korevaar, Daniel A.
    Cohen, Jeremie F.
    [J]. CLINICAL CHEMISTRY, 2015, 61 (12) : 1446 - 1452
  • [10] BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416